Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

布累迪宁 - NMPA Drug Approval Details

Approvals/NMPA/Mizoribine Tablets

Approved

化学药品

Mizoribine Tablets

ASAHI KASEI PHARMA CORPORATION🇨🇳 National Medical Products Administration

Approval Date: Sep 24, 2024
Approval ID: 8dLWTQEadgX
Company: ASAHI KASEI PHARMA CORPORATION
Type: 化学药品

Approval Details

Approval Id: 8dLWTQEadgX
Approval Number: 国药准字HJ20140244
Generic Name: 咪唑立宾片
Generic Name En: Mizoribine Tablets
Trade Name: 布累迪宁
Drug Type: 化学药品
Dosage Form: 片剂
Strength: 50mg
Reg Date: 2024-09-24
Expired Date: 2029-09-23
Company Name: ASAHI KASEI PHARMA CORPORATION
Company Detail Path: /organization/asahi-kasei-pharma-corporation

Approved

Quick Info

Agency

NMPA

Country

🇨🇳

Approval Date

Sep 24, 2024

Approval ID

8dLWTQEadgX

Type

化学药品

Back to NMPA Approvals